H&H Pharmaceuticals, LLC v. Chattem Chemicals, Inc.

CourtCourt of Appeals for the Ninth Circuit
DecidedApril 23, 2024
Docket23-15055
StatusUnpublished

This text of H&H Pharmaceuticals, LLC v. Chattem Chemicals, Inc. (H&H Pharmaceuticals, LLC v. Chattem Chemicals, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
H&H Pharmaceuticals, LLC v. Chattem Chemicals, Inc., (9th Cir. 2024).

Opinion

NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS APR 23 2024 MOLLY C. DWYER, CLERK U.S. COURT OF APPEALS FOR THE NINTH CIRCUIT

H&H PHARMACEUTICALS, LLC, No. 23-15055

Plaintiff-Appellant, D.C. No. 2:16-cv-02148-GMN-VCF v.

CHATTEM CHEMICALS, INC.; SUN MEMORANDUM* PHARMACEUTICALS INDUSTRIES, INC.,

Defendants-Appellees.

Appeal from the United States District Court for the District of Nevada Gloria M. Navarro, District Judge, Presiding

Argued and Submitted March 8, 2024 Las Vegas, Nevada

Before: M. SMITH, BENNETT, and COLLINS, Circuit Judges.

H&H Pharmaceuticals, LLC (H&H) appeals from the district court’s final

judgment in favor of Chattem Chemicals, Inc. (Chattem) and its parent entity, Sun

Pharmaceuticals, Inc. (Sun). We have jurisdiction pursuant to 28 U.S.C. § 1291.

We review de novo the district court’s decision to dismiss for failure to state a claim.

* This disposition is not appropriate for publication and is not precedent except as provided by Ninth Circuit Rule 36-3. Transmission Agency of N. Cal. v. Sierra Pac. Power Co., 295 F.3d 918, 927 (9th

Cir. 2002). We review de novo the district court’s decision to grant summary

judgment. Weiner v. San Diego Cnty., 210 F.3d 1025, 1028 (9th Cir. 2000). Because

the parties are familiar with the facts, we do not recount them except as necessary to

provide context. We affirm in part, vacate in part, and remand to the district court

for further proceedings consistent with this memorandum.

1. It is well-established that the citizenship of a limited liability company,

such as H&H, is determined by the citizenship of its members, not by “the state in

which it was formed or does business.” NewGen, LLC v. Safe Cig, LLC, 840 F.3d

606, 612 (9th Cir. 2016), as amended. Neither H&H’s complaint nor Chattem’s

petition for removal alleged any facts to indicate the citizenship of H&H’s members.

Accordingly, the district court did not have enough information at the time of

removal to conclude that the diversity-of-citizenship requirement of 28 U.S.C.

§ 1332(a)(1) was satisfied.

However, subsequent developments in the record have assured us that it was.

During discovery, H&H confirmed that it only had two members, both of whom had

been residing in Nevada for many years at the time H&H filed suit. Accordingly,

H&H is a citizen of Nevada. Given that neither Chattem nor Sun is incorporated or

headquartered in Nevada, we are satisfied that complete diversity of citizenship was

met, and the district court was empowered to exercise diversity jurisdiction over

2 H&H’s action.

2. Nevada’s Uniform Trade Secrets Act (UTSA) expressly “displaces

conflicting tort, restitutionary, and other law of this state providing civil remedies

for misappropriation of a trade secret.” Nev. Rev. Stat. § 600A.090(1). The Nevada

Supreme Court has therefore held that “[t]he plain language of NRS 600A.090

precludes a plaintiff from bringing a tort or restitutionary action ‘based upon’

misappropriation of a trade secret beyond that provided by the UTSA.” Frantz v.

Johnson, 999 P.2d 351, 357 (Nev. 2000) (quoting Nev. Rev. Stat. § 600A.090(2)(b)).

A tort or restitutionary action is “based upon” misappropriation of a trade secret if

“[t]he factual circumstances underlying the claims . . . are completely dependent on

the facts concerning misappropriation of trade secrets.” Id. at 357 n.3.

Here, all of H&H’s causes of action sounding in tort and restitution are based

upon H&H’s allegations that Chattem and Sun misappropriated H&H’s confidential

information, which includes H&H’s conversion methods for converting raw opium

and concentrate of poppy straw into opiate-based raw materials. In its amended

complaint, H&H expressly defined these conversion methods as “trade secrets, as

defined in the Nevada Uniform Trade Secrets Act.” Moreover, throughout this

litigation, H&H has argued that it is entitled to the profits Chattem and Sun have

enjoyed because of their misappropriation of H&H’s confidential information—a

theory of recovery that is available in a modified form under the UTSA. See Nev.

3 Rev. Stat. § 600A.050(1) (“Damages include both loss caused by misappropriation

and unjust enrichment caused by misappropriation that is not taken into account in

computing the loss.”).

We conclude that the UTSA displaced H&H’s common-law causes of action

for tortious breach of the implied covenant of good faith and fair dealing, for breach

of fiduciary duty, for constructive fraud, for fraudulent concealment, for fraudulent

misrepresentation, for negligent misrepresentation, for negligence, for unjust

enrichment, and for civil conspiracy. See Frantz, 999 P.2d at 358 (clarifying that a

claim for civil conspiracy is displaced by the UTSA because it is grounded in tort).

We therefore decline to reach the merits of H&H’s arguments on appeal about the

availability of, the elements of, and the pleading standards applicable to H&H’s tort

and restitutionary causes of action, since they are no longer operative under Nevada

law.

Given that the district court failed to recognize the displacing effect of the

UTSA in adjudicating H&H’s tort and restitutionary causes of action, we vacate the

district court’s judgment with respect to those causes of action and remand to the

district court to determine, in the first instance, whether H&H has already adequately

pled a statutory UTSA claim in its amended complaint in light of H&H’s allegation

that its conversion methods are “trade secrets, as defined in the Nevada Uniform

Trade Secrets Act,” and if not, whether H&H should be granted leave to replead such

4 a claim.

3. While the UTSA expressly “displaces conflicting tort, restitutionary,

and other law of this state providing civil remedies for misappropriation of a trade

secret,” Nev. Rev. Stat. § 600A.090(1), the UTSA does not displace “[c]ontractual

remedies,” even if they are “based upon misappropriation of a trade secret,” id.

§ 600A.090(2)(a). Such contractual remedies include those that may arise from

contractual breaches of the implied covenant of good faith and fair dealing. See

Frantz, 999 P.2d at 358 n.4. Accordingly, we must still evaluate whether the district

court erred when it granted summary judgment to Chattem on H&H’s causes of

action for breach of contract and for contractual breach of the implied covenant of

good faith and fair dealing on the basis that H&H failed to present any probative

evidence on the element of damage.

The only evidence of damage H&H presented to the district court in

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
H&H Pharmaceuticals, LLC v. Chattem Chemicals, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/hh-pharmaceuticals-llc-v-chattem-chemicals-inc-ca9-2024.